Iran Pharmaceutical Market Access and Registration Pathway

AI Citation Summary

• Country: Iran Pharmaceutical Market Access and Registration Pathway
• Product line: Pharmaceuticals
• Regulator / source: Regulatory maturity: Medium-high but operationally complex. Iran Food and Drug Administration (IFDA) / Food and Drug Organization (FDO), under the Ministry of Health and Medical Education (MOHME), shape product registration, importation, pricing, traceability, and post-market duties.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
• Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
• Local requirement: Local Market and Importer Map
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Market profile: Iran is one of the larger pharmaceutical markets in the Middle East. Local generic capability is strong, while imported products tend to concentrate around innovative medicines, specialty products, biologics, plasma-derived medicinal products, shortage medicines, and products not reliably supplied by local manufacturers.
• Regulatory maturity: Medium-high but operationally complex. Iran Food and Drug Administration (IFDA) / Food and Drug Organization (FDO), under the Ministry of Health and Medical Education (MOHME), shape product registration, importation, pricing, traceability, and post-market duties.
• Core decision: Iran entry is not simply a distributor search. A project must assess local substitutes, authorised agent control, Iran Registration Code (IRC), pricing approval, import permission, distribution channels, payment path, and sanctions compliance together.

Regulator

• Regulatory system: Iran Food and Drug Administration (IFDA) / Food and Drug Organization (FDO), under Ministry of Health and Medical Education (MOHME)
• Key concepts: Product License Holder (PLH), Marketing Authorization Holder (MAH), Authorized Agent, Marketing Authorization License, Iran Registration Code (IRC), Responsible Pharmacist, Iran Drug List, TTAC traceability
• Commercial boundary: Iran-related pharmaceutical transactions can require sanctions and counterparty screening. Humanitarian or medicine-related authorisations do not replace checks on the counterparty, bank, end user, product use, and transaction structure.

Local Market and Importer Map

Iranian pharmaceutical importers can be grouped into three practical categories:

Type	Main function	Typical product fit
Large registration / import / promotion companies	Represent foreign products for registration, import, pricing interaction, hospitals, and specialty channels	Innovative drugs, specialty drugs, complex dosage forms, multinational brands
Specialty medicine / biologic / plasma-product importers	Handle cold chain, hospital access, blood products, rare diseases, and high-complexity supply chains	Oncology, immunology, plasma-derived medicinal products, rare disease products, renal and transplant medicines
API / local manufacturing / under-license partners	Support local production, technology transfer, contract manufacturing, complex generics, and biosimilars	Generics, complex generics, biosimilars, long-term supply-security projects

The following company pool comes from local market research and public company signals. It is a BD and counterparty-screening starting point, not a fully verified ranking table:

Company	Chinese label	Initial positioning	Possible engagement direction
Behestan Darou	贝赫斯坦药业	Innovative and specialty-drug registration / import / promotion platform	Oncology, immunology, rare disease, specialty chronic care, complex dosage forms
Cobel Darou	科贝尔药业	Prescription and specialty-drug platform connected with multinational companies	Cardiovascular, diabetes, oncology, respiratory, renal care, vaccines
Shafayab Gostar	沙法亚布	Innovative drug registration, import and distribution	Innovative medicines, hospital specialty products, multinational brand agency
Darman Ara	达尔曼阿拉	Plasma products, biologics, medical nutrition, and adjacent medical products	Albumin, immunoglobulin, coagulation factors, biologics
Behestan Plasma	贝赫斯坦血浆	PDMP / plasma-derived medicinal products	Plasma products, rare disease and hematology products
Ahran Tejarat	阿赫兰贸易	Import, distribution, agency, and partial local manufacturing	Women's health, nephrology, orthopedics, urology, CNS, supplements
Actoverco	阿克托沃	Local manufacturer with import, generic, and biosimilar capabilities	Local production, technology transfer, complex generics
Tose'e Amin Darou Arad / TADA	阿明达鲁阿拉德	Registration, import, contract manufacturing, and local production	Smaller market-entry and localisation projects
Novo Nordisk Pars	诺和诺德伊朗公司	Local multinational affiliate	Diabetes, insulin, GLP-1; usually not a third-party agency target
Rougine / Rojin Darou / Plasma	鲁金 / 罗金系	Import, plasma, or local-manufacturing related business	Specialty medicines, plasma products, under-license products

Registration Pathway

Import authorisation structure

Import authorisation in Iran should be separated into at least two layers:

1. Commercial authorisation. The foreign PLH / MAH or product owner appoints a local Iranian agent. The authorisation should define product, dosage form, strength, term, territory, scope of authority, and termination mechanics.
2. Regulatory authorisation. The local agent submits the registration package to IFDA / FDO / MOHME and seeks a Marketing Authorization License and IRC. Without an IRC, a product generally cannot enter the normal commercial distribution and prescription system.

After IRC issuance, the project still needs pricing approval, import batch permission, label / leaflet compliance, pharmacovigilance, TTAC traceability, distribution contracts, and payment routing.

Basic pathway for foreign medicines

1. Check local substitution first
   Iran has a strong local generic system. If low-cost local equivalents already exist, the commercial and approval path for an imported equivalent may become substantially harder. A foreign supplier should first check whether the product is in the Iran Drug List, whether local equivalents exist, and whether the product addresses a shortage or specialty-treatment need.

2. Select the local authorised agent
   The local partner should have pharmaceutical import or registration capability, a Responsible Pharmacist, past IRC cases, distribution or hospital access, pricing-committee experience, and pharmacovigilance capacity. Do not grant authority based only on trade quotes or verbal channel claims.

3. Prepare the authorisation chain and administrative package
   The authorisation letter, PLH / MAH data, manufacturer details, CPP, GMP evidence, global registration status, import application, product information, price materials, label, and Persian leaflet should remain consistent. A weak authorisation chain can block registration and complicate later agent replacement.

4. Prepare technical evidence
   Quality, CMC, stability, GMP, nonclinical, clinical, BE, or waiver evidence should be prepared by product type. Generics, biosimilars, specialty medicines, and new drugs have different evidence priorities.

5. Submit, manage technical review, and obtain IRC
   The local agent usually submits the dossier, tracks questions, and manages administrative and technical responses. A Marketing Authorization License and IRC move the project into pricing, import, distribution, and launch execution.

6. Price, import, and maintain post-market duties
   Iran commercial viability often depends on pricing and payment feasibility. The importer must also manage import batches, pharmacovigilance, ADR / PSUR duties, label maintenance, variations, renewal, and traceability obligations.

Dossier checklist

Module	Key documents	Execution notes
Authorisation and administration	PLH / MAH authorisation letter, local agent information, Responsible Pharmacist, CPP, GMP, global registration status, application forms	Authorisation scope, product name, dosage form, strength, manufacturing site, and holder details must align
Product and quality	CTD / CMC, formulation, process, specifications, analytical methods, validation, stability, packaging	Stability, packaging, and storage should fit Iran's supply chain and climate
Manufacturing and GMP	API, finished product, packaging, release sites, GMP certificates, contract manufacturing relationships	Multi-site or under-license structures need clear responsibility mapping
Clinical / BE	Clinical evidence, BE, waiver rationale, literature, foreign assessment materials	Generics focus on quality and BE; new and specialty medicines need stronger clinical and benefit-risk arguments
Pricing and market	Proposed price, international prices, therapeutic value, local substitutes, shortage status	Pricing drives commercial feasibility and should not be left until after approval
Label and traceability	Persian leaflet, packaging mock-up, batch information, traceability data, TTAC-related materials	Label, leaflet, import data, and approved content must remain consistent
Post-market	PV SOPs, ADR / PSUR, recall, variation, renewal, agent-change mechanics	The local agent must have continuing maintenance capability

Local generics and under-license production

Iranian local generics usually do not depend on a foreign commercial authorisation. Domestic manufacturers can pursue local manufacturing approval based on the INN / generic name, GMP, quality review, BE / clinical / PMS evidence where applicable, pricing approval, and traceability coding.

Under-license local production is different. A foreign PLH / MAH or brand owner grants technology, brand, or production rights to an Iranian company, and the Iranian company then seeks local production and marketing approval. This route is relevant when a supplier wants to reduce import constraints, build long-term supply, or improve policy acceptance through localisation.

Specialty medicines, shortages, and named-patient routes

Specialty medicines should not be treated as one normal import category. Separate four routes:

1. Normally registered specialty imports: oncology, immunology, biologics, rare disease products, blood products, transplant medicines, renal / dialysis products, and similar medicines still need local agent, registration, IRC, pricing, and distribution.
2. New medicines not yet marketed in Iran: committee or technical review may consider efficacy, safety, comparator products, foreign approval history, patient need, and pharmacoeconomics.
3. Shortage or limited-volume special imports: temporary shortage, urgent need, or limited clinical supply may be possible, but this does not equal long-term commercial market authorisation.
4. Plasma-derived and biologic localisation / toll-manufacturing models: these often involve cold chain, GMP, plasma source, domestic and foreign manufacturing, batch return, and more complex compliance structures.

Local agent and control risks

The biggest recurring risk in Iran is agent lock-in. Contracts should define:

• who controls IRC, dossier, system account, and regulatory correspondence;
• who manages pricing approval, import permission, pharmacovigilance, recall, and renewal;
• whether the PLH / MAH can terminate authority if the agent fails to file, respond, purchase, or pass compliance checks;
• whether registered products can be transferred to another agent and which termination / appointment letters are required;
• whether exclusivity is tied to minimum registration, purchase, and launch milestones;
• who owns payment, banking, end-user, beneficial-owner, and sanctions screening.

Partner due-diligence checklist

Check	Purpose
Pharmaceutical import licence / IFDA or MOH-related authorisation	Confirms whether the counterparty can legally import and file products
Responsible Pharmacist licence	Confirms technical responsibility for registration and post-market duties
Past IRC examples	Verifies actual product-registration execution
Authorized Agent / MAH agency capability	Shows whether the counterparty can submit and maintain the dossier
Distribution contract or hospital-access capability	Registration approval does not itself create sales
Same-indication local competitors and local equivalents	Tests import approval and pricing space
Pricing committee experience	Tests post-approval commercial viability
Cold-chain, GDP, hospital access, and PV systems	Critical for specialty medicines, biologics, and injectables
Exclusivity terms	Avoids premature full-product, full-market, long-term exclusivity
Sanctions, payment, and beneficial-owner screening	Reduces banking, compliance, and supply interruption risk

Recommended supplier strategy

Do not grant an Iranian importer full-product, full-market, long-term exclusivity at the first contact. A safer sequence:

1. Product screening: confirm Iran Drug List status, local equivalents, shortage status, and specialty-medicine potential.
2. Non-exclusive technical assessment: sign an NDA and share limited materials for registration feasibility review.
3. Product-level authorisation: authorise only selected products, dosage forms, and time windows.
4. Milestones: define registration submission, deficiency response, approval, purchase, and launch milestones.
5. Agent-replacement rights: predefine termination and transfer mechanics for non-filing, non-response, non-purchase, or compliance failure.

Common failure points

1. Selecting a trade intermediary without verifying registration and IRC capability.
2. Treating commercial appointment as government marketing authorisation.
3. Ignoring local generic equivalents and overestimating import and pricing feasibility.
4. Granting long-term exclusivity before submission milestones, leaving the product locked by a passive agent.
5. Failing to resolve payment, banking, end-user, and sanctions screening before launch.
6. Designing specialty-medicine supply as normal commercial import while ignoring shortage, named-patient, and hospital-access differences.
7. Handling IRC, pricing, import permits, and distribution contracts as separate disconnected workstreams.

Sources and verification date

• Pharmexcil / Iran FDA pharmaceutical registration presentation: https://pharmexcil.com/uploadfile/ufiles/11_IranFDARegulationsforregistrationofPharmaceuticalproducts_PargolBina_Iran.pdf
• Iranian pharmaceutical laws and regulations overview: https://pmc.ncbi.nlm.nih.gov/articles/PMC8918968/
• OFAC Iran sanctions FAQ 637: https://ofac.treasury.gov/faqs/637
• OFAC selected general licenses: https://ofac.treasury.gov/selected-general-licenses-issued-ofac
• Behestan Darou company site: https://behestandarou.ir/en/
• Darman Ara company site: https://darmanara.com/about-us/

Updated: 2026-07-01. This page combines local market research with public regulatory sources for market-entry screening. Before granting authority, filing, payment, or supply, recheck current IFDA / FDO / MOHME requirements, company qualifications, sanctions status, end user, and banking path.